The True Cost of GLP-1, Once the Dose Climbs

The landing-page price is a starting gun, not a finish line

Every telehealth ad sells you the first month. The number in the hero image — the one that looks like a streaming subscription — is almost always the lowest starting dose, on an introductory tier, before the taper up begins. It is a real price. It is just not your price for very long. A mother budgeting for a year of care needs to look past the starting gun to where the bill actually settles, because for most people the dose does not stay where it started.

The sticker price is a starting gun. The only number that matters is the one you are still paying at the maintenance dose.

The dose climbs by design, and the invoice usually climbs with it

GLP-1 medications work by dose. In the STEP 1 trial, once-weekly semaglutide was titrated up to 2.4 mg and produced a mean body-weight reduction of roughly 15% over 68 weeks¹. Tirzepatide went further in SURMOUNT-1, with mean reductions near 20% at the highest dose². Those headline results are maintenance-dose results — they describe what happens once you have climbed the ladder, not while you are on the bottom rung. A pricing model that charges more for higher doses is, in effect, charging you more precisely as the medication starts to work. That is the quiet mechanism that turns a "start from $99" plan into something a family feels every month.

The step-up is not a rumor — it is printed on the manufacturers' own price lists

You do not have to take this on faith, and you do not have to squint at a telehealth startup's fine print to find it. The companies that make these drugs publish the ladder themselves.

Novo Nordisk's self-pay terms for Wegovy state that patients new to the offer "pay $199 for each month of 0.25 mg & 0.5 mg", that the "offer is for 2 monthly fills", and that the price then becomes "$349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg"⁵. Read that slowly, because it is the argument of this piece in one sentence written by the manufacturer: two fills at one number, every month afterwards at a number three-quarters higher — and the increase arrives on schedule whether or not your dose has moved.

Eli Lilly prices Zepbound by the dose outright. Its self-pay terms quote "as low as $299" for a one-month fill of the 2.5 mg pen, $399 for 5 mg, and $449 for 7.5 mg and above — with that $449 rate conditional on completing your refill "within 45 days of the delivery/received date of your previous" fill⁶. So the ladder runs in two directions at once: the price rises as you titrate, and it can rise again if life gets in the way of an on-time refill. Lilly also defines one month as 28 days rather than a calendar month, which quietly puts a thirteenth fill in a year.

None of this is hidden. It is simply not what is on the landing page. (Both sets of terms carry their own expiry dates and change often; check the current figure before you plan around it.)

"I stopped only because I had to pay for my tuition"

Numbers describe the ladder. They do not describe what it is like to be standing on it.

In a 2026 qualitative study published in JAMA Network Open, researchers analyzed video interviews with 30 adults across 15 US states who were taking or had taken a GLP-1, 19 of them women. One of the eight themes they identified was blunt: access challenges and cost can be prohibitive⁷. One participant described the medication working and then simply losing to a competing bill: "I took it from January to April, and I lost 70 pounds. And then I stopped only because I had to pay for my tuition." Another described what it took to get the prescription at all — "I had to actually advocate for myself to get it because it's very, very, very expensive."

That first quote is the shape of the problem for a household. Nothing went wrong medically. The drug worked; seventy pounds came off. What ended it was a due date on a different invoice — the kind of thing every family budget has four or five of.

This is a standing expense, not a course of antibiotics

The most expensive assumption a family can make is that GLP-1 treatment is a short push — a few months to a goal, then done. The evidence says otherwise. When semaglutide was withdrawn and replaced with placebo in the STEP 4 trial, participants regained a substantial share of the weight they had lost³. Tirzepatide behaved the same way in SURMOUNT-4: stopping the drug reversed much of the progress⁴. Read together, these trials reframe the whole budgeting question. You are not pricing a treatment with an end date. You are pricing a recurring line item that, like a phone bill or a gym membership, has to survive every tight month — the holidays, the car repair, the summer the kids are home and the grocery bill balloons.

Which is why the tuition answer is not an outlier. It is what a standing cost does when it meets a household that has more than one obligation.

What a budget-proof price actually looks like

Once you accept that this is a standing cost that scales with the dose, the shape of a good price becomes obvious: flat, all-in, and identical at the full maintenance dose as it was at the start. It is not always the lowest sticker on day one; a bare introductory tier somewhere else can undercut it for exactly one month, or exactly two fills. But the number you sign for is the number you are still paying at maintenance, and that is the only comparison that survives a family budget.

The complication is that a price can hold at every dose and still not be the bill. A separate clinic fee alongside a flat medication rate, a headline that is really a twelve-month prepaid rate, the same plan priced two ways on two of a company's own pages — the five ways a flat price stops being flat sets out the patterns and names who uses which.

The ladder now has a rung above the flat one

There is one update that belongs here rather than there, because it changes the argument of this piece rather than illustrating it.

When the price list quoted above was checked, the flat tier was the top of the ladder. It no longer is. Novo Nordisk's savings terms, read on 2026-08-21, now read: $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg, and $399 per month for Wegovy HD 7.2 mg⁵.

A sixth dose, approved after that ladder was set, priced outside it.

So the advice to find a price that is flat at every dose still holds — but "every dose" is a moving target, and a comparison written before the 7.2 mg approval is describing a ladder that has since grown. If you are titrating toward the highest approved dose, check whether your program's flat rate follows you all the way up, because the manufacturer's does not.

And a "month" may be twenty-eight days

The same footnote answers a question this piece has been asking since it was written.

"One month defined as 1 box of 4 pens of Wegovy."⁵

Four pens, one a week. Twenty-eight days. Which means roughly thirteen fills a year, not twelve — and at $349, that is about $4,537 rather than the $4,188 anyone would compute from "per month."

Three hundred and forty-nine dollars a year, in one extra fill that no budget built from a monthly figure contains. It is disclosed, plainly, in a footnote. It is simply not in any comparison table in this market.

Two current examples of the shapes above, checked 2026-08-21: FitFlow holds $99 semaglutide at every dose and publishes no other figure anywhere, including in its own code; Nouri prices flat at any dose too, but its headline $120 is a six-month prepay against a $175 standing rate.

The questions to ask before you enter a card number

Ask what the medication costs at the highest maintenance dose, not the starting dose. Ask how long the introductory rate lasts — in fills, not in vague months — and what the price becomes the day after it ends. Ask whether switching molecules, from semaglutide to tirzepatide, resets your price or your progress. Ask whether a late refill costs you the rate, and whether a "month" means 28 days or a calendar month. And ask how you cancel, in plain language, before you ever need to. A program that answers all five in writing is one you can plan a year around. A program that answers none of them is selling you the starting gun and hoping you never check the finish line.